Aldehyde-Functionalized Substrate for Antibody Purification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for purifying biological liquids, particularly plasma, are inadequate in removing antibodies against saccharide determinants, leading to risks during blood transfusions and organ transplants, and are inefficient and costly due to the low affinity between anti-saccharide antibodies and their antigens.
Innovation Solution
A support with covalently grafted oligosaccharides and free aldehyde functions is used to stabilize and capture IgG and IgM antibodies, allowing for effective purification by forming covalent bonds with specific amino acids on the antibodies, thereby reducing the risk of immune reactions and improving the efficiency of antibody removal.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional purification methods are used to remove antibodies from biological fluids, then the purification process can be performed, but the removal of anti-saccharide antibodies is inadequate leading to immune reactions
Solution Approach 1:
The patent uses a solid support with free aldehyde groups as an intermediary substance that mediates the binding and removal of anti-saccharide antibodies. The aldehyde groups form covalent bonds with amino acids on the antibody molecules, enabling effective capture and removal of harmful antibodies from biological fluids while preventing immune reactions.
Solution Approach 2:
The patent changes the chemical parameters of the purification system by introducing solid supports with free aldehyde groups that can form covalent bonds with antibodies. This parameter change from conventional non-covalent binding methods to covalent bonding significantly improves the effectiveness of antibody removal, particularly for anti-saccharide antibodies.
2Reliability
If a large excess of saccharide antigen is used to remove anti-saccharide antibodies, then more antibodies can be bound, but the complexity and cost of synthesizing complex saccharide molecules increases
Solution Approach 1:
The patent extracts the essential functional component (aldehyde group) from the complex saccharide antigen system. Instead of using complete saccharide antigens that require complex synthesis, the invention uses simplified solid supports with free aldehyde groups that retain the ability to bind antibodies through covalent bonding, eliminating the need for complex saccharide synthesis while maintaining antibody capture efficiency.
Solution Approach 2:
The solid support with free aldehyde groups serves as an intermediary that replaces the complex saccharide antigen. This intermediary maintains the essential antibody-binding function through covalent bonding while eliminating the synthesis complexity associated with producing complete saccharide antigen molecules.
3Reliability
If IgG antibodies are targeted for removal, then blood transfusion safety is improved, but the low affinity constant between anti-saccharide antibodies and antigens makes removal difficult
Solution Approach 1:
The patent fundamentally changes the binding mechanism parameter from low-affinity non-covalent interactions to high-strength covalent bonding. The free aldehyde groups on the solid support form covalent bonds with amino acids on IgG antibodies, dramatically increasing the binding strength and enabling effective removal of anti-saccharide antibodies despite their naturally low affinity constants.
Solution Approach 2:
The patent converts the naturally low affinity between anti-saccharide antibodies and antigens into a benefit by using a different chemical mechanism. Instead of relying on the weak natural affinity, the invention uses covalent bonding through free aldehyde groups, which provides strong, irreversible binding that overcomes the affinity limitation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The support effectively stabilizes and removes antibodies against blood group determinants, reducing the risk of hemolytic shock and immune reactions, and provides a universal plasma solution compatible with all blood groups, enhancing the safety and cost-effectiveness of blood transfusions and organ transplants.
Implementation Method 1
The free aldehyde functions -CHO present on the solid phase interact with the antibodies to stabilise the binding between the oligosaccharides and the antibodies to which they bind. The stabilisation of the binding between the oligosaccharides and the antibodies may result from the formation of covalent bonds
Implementation Method 2
A support with covalently grafted oligosaccharides and free aldehyde functions is used to stabilize and capture IgG and IgM antibodies
Implementation Method 3
The separation of anti-saccharide antibodies, considered undesirable, from a biological fluid retaining all its properties, is a major therapeutic advance
Data Source
Figure 1~2
Figure 3
AI summary
The invention relates to a substrate for the purification of a body fluid, comprising a solid phase to which molecules of at least one oligosaccharide that can bind to one or more antibodies are covalently grafted, said solid phase carrying free aldehyde (-CHO) functions. The invention also relates to a method for producing such a substrate, the use of such a substrate in stabilising the antibody/oligosaccharide bond, and a method for purifying a body fluid, in which the body fluid is brought into contact with at least one substrate according to the invention, such as to capture antibodies present in the body fluid by means of bond(s) with at least some of the oligosaccharide molecules grafted to the solid phase.